November 2026 · Press release
Protego Presents New Data at ISA 2026 that Advances Evidence for Light-Chain Stabilization with PROT-001 in AL Amyloidosis
Protego Biopharma announced results from five presentations at the XX
International Symposium on Amyloidosis (ISA 2026). PROT-001, the company's
investigational oral small molecule for AL amyloidosis, demonstrated an
acceptable safety and tolerability profile in a Phase 1 study in healthy
volunteers. In human cardiomyocyte and plasma cell studies, PROT-001 reduced
markers of stress and toxicity and demonstrated compatibility with
standard-of-care bortezomib. Additional presentations covered the
AmyLiteDx™ assay and NT-proBNP as an early clinical biomarker of cardiac
response.
"The data presented at ISA 2026 strengthen the rationale for SHIELD-AL, where
we will evaluate whether this approach can deliver earlier and deeper cardiac
responses," said Brent J. Warner, MBA, Chief Executive Officer of Protego.
Read Full Press Release
November 2026 · Press release
Protego to Highlight PROT-001's Potential to Target Light Chain Toxicity in AL Amyloidosis at ISA 2026
Protego Biopharma announced five presentations at the XX International
Symposium on Amyloidosis (ISA 2026), taking place November 15–18, 2026.
They include Phase 1 results in healthy volunteers characterizing the clinical
profile of PROT-001, an investigational first-in-class lambda light chain
kinetic stabilizer; preclinical presentations evaluating its potential to reduce
light chain-induced cardiac toxicity and its compatibility with bortezomib-based
treatment; and the AmyLiteDx™ assay for analyzing amyloidogenic light chains.
"As we initiate SHIELD-AL, we believe our approach could help patients achieve
faster and deeper organ responses beyond standard of care alone," said Brent J.
Warner, MBA, Chief Executive Officer of Protego.
Read Full Press Release
October 2026 · Press release
Protego Announces FDA IND Clearance for Phase 2/3 Study of PROT-001 in AL Amyloidosis
Protego Biopharma announced that the U.S. Food and Drug Administration (FDA)
has cleared its Investigational New Drug (IND) application for PROT-001,
enabling the company to initiate SHIELD-AL, its global pivotal Phase 2/3
study, in newly diagnosed light chain (AL) amyloidosis patients. SHIELD-AL
is a randomized, double-blind, placebo-controlled study of PROT-001, an
investigational oral lambda light chain stabilizer, as an add-on to
standard-of-care plasma cell-directed therapy.
"SHIELD-AL will evaluate whether this complementary approach with PROT-001
can help patients achieve deeper and faster organ responses while reducing
cardiovascular complications beyond standard of care alone," said Brent J.
Warner, MBA, Chief Executive Officer of Protego Biopharma.
Read Full Press Release
June 2026 · Press release
Protego Biopharma Appoints Jae B. Kim, MD, as Chief Medical Officer
Protego Biopharma announced the appointment of Jae B. Kim, MD, as Chief
Medical Officer. A board-certified cardiologist, Dr. Kim brings deep
experience advancing novel therapies for cardiovascular and rare diseases,
having contributed to the development and/or approval of medicines including
Camzyos, Amvuttra, Leqvio, and Repatha across leadership roles at Septerna,
Design Therapeutics, Avidity Biosciences, Alnylam, MyoKardia, and Amgen.
"He joins Protego at an opportune time to help advance our lead program
PROT-001, a small molecule pharmacological chaperone designed to treat light
chain amyloidosis, into pivotal studies this year," said Brent J. Warner,
Chief Executive Officer of Protego.
Read Full Press Release
December 2025 · Media coverage
Protego Bio Raises $130 Million Oversubscribed Series B Financing
Protego Bio announced the completion of a $130 million oversubscribed
Series B financing to advance PROT-001, our first-in-class AL amyloidosis
program, into pivotal clinical studies. The financing round demonstrates
strong investor confidence in our scientific approach and clinical strategy.
"This significant investment enables us to advance PROT-001 through pivotal
development and brings us closer to delivering a transformative therapy for
patients with AL amyloidosis," said Brent Warner, Chief Executive Officer.
Read the coverage
November 2021 · Press release
Protego Bio Raises $51 Million Series A Financing
Protego Bio announced the completion of a $51 million Series A financing
to advance the treatment of protein misfolding diseases. The financing was
led by premier healthcare investors and will support the advancement of our
lead programs and expansion of our discovery pipeline.
The Series A financing enables Protego to build on the validated mechanism
of pharmacological chaperones, extending this proven approach to new
therapeutic targets with significant unmet medical need.
Read Full Press Release